Literature DB >> 8002088

Prolonged treatment of chronic Pseudomonas aeruginosa osteomyelitis with a combination of two effective antibiotics.

R F Lucht1, A Fresard, P Berthelot, F Farizon, G Aubert, G Dorche, G Bousquet.   

Abstract

Emergence of Pseudomonas aeruginosa resistant to antibiotic monotherapy is one of the causes of therapeutic failure in chronic P. aeruginosa osteomyelitis. We report 15 cases of chronic (> 3 months of evolution) biopsy culture proven P. aeruginosa osteomyelitis included in an open prospective study evaluating the efficacy of prolonged treatment (> 4 months) with two effective antibiotics in combination. Mean post-treatment follow-up was 38 months. A regimen of cefsulodin in combination with oral ofloxacin was used for six patients, cefsulodin-pefloxacin for three patients, cefsulodin-ciprofloxacin for one patient, piperacillin-pefloxacin for one patient, cefsulodin-fosfomycin for one patient, imipenem-ciprofloxacin for two patients and amoxicillin-ciprofloxacin-fosfomycin for one patient as home therapy. The clinical cure rate of 73% and bacteriological cure rate of 93% are far superior to those previously described in the literature. We did not observe adverse drug reactions. We think that a prolonged use of two effective antibiotics in combination is a safe and improved therapeutic schedule for chronic P. aeruginosa osteomyelitis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8002088     DOI: 10.1007/BF01739916

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  19 in total

Review 1.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

2.  Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis.

Authors:  L O Gentry; G G Rodriguez
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

3.  Totally implantable vascular access for antimicrobial infusion at home and prevention of systemic candidosis.

Authors:  F Lucht; N Vergely; H Rousset; G Bousquet; J G Balique
Journal:  Lancet       Date:  1989-03-25       Impact factor: 79.321

4.  Intravenous ciprofloxacin therapy in severe infections.

Authors:  F Gudiol; C Cabellos; R Pallares; J Linares; J Ariza
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

5.  Treatment of skin, skin structure, bone, and joint infections with ceftazidime.

Authors:  L O Gentry
Journal:  Am J Med       Date:  1985-08-09       Impact factor: 4.965

Review 6.  Ciprofloxacin for the treatment of osteomyelitis: a review.

Authors:  M T Hessen; M E Levison
Journal:  J Foot Surg       Date:  1989 Mar-Apr

7.  Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis.

Authors:  R N Greenberg; A D Tice; P K Marsh; P C Craven; P M Reilly; M Bollinger; W J Weinandt
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

8.  Imipenem/cilastatin in the treatment of osteomyelitis.

Authors:  R R MacGregor; L O Gentry
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

9.  Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu; M F Parry; W Mandell
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

10.  Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

Authors:  H Giamarellou; N Galanakis; C Dendrinos; J Stefanou; E Daphnis; G K Daikos
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

View more
  2 in total

1.  Remission after treatment of osteoarticular infections due to Pseudomonas aeruginosa versus Staphylococcus aureus: a case-controlled study.

Authors:  Khalid Seghrouchni; Christian van Delden; Dennis Dominguez; Mohamed Benkabouche; Louis Bernard; Mathieu Assal; Pierre Hoffmeyer; Ilker Uçkay
Journal:  Int Orthop       Date:  2011-10-05       Impact factor: 3.075

Review 2.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.